To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.

Legislative bill overview

HR 7877 directs the HHS Secretary to create a demonstration program that would require Medicaid to cover wound care treatments for epidermolysis bullosa (EB), a rare genetic disorder causing severe blistering and skin fragility. The bill tests whether mandating this coverage improves health outcomes and reduces costs across participating states.

Why is this important

Epidermolysis bullosa patients face debilitating wounds requiring expensive ongoing care, and Medicaid coverage gaps create significant financial and health burdens for affected families. A successful demonstration could establish a model for ensuring vulnerable populations with rare diseases receive necessary treatments while providing data on cost-effectiveness that could inform future policy decisions.

Potential points of contention

• Cost and federal responsibility: States may resist mandatory coverage expansion without federal funding guarantees, raising questions about how demonstration costs are shared
• Scope definition: "Wound care treatment" is broad; disagreement may arise over which specific therapies, medications, and devices must be covered
• Demonstration parameters: Questions about which states participate, how long the program runs, and what metrics determine success could affect program viability and scalability